Neurology Monitoring Market Size & Growth Forecast to 2033

Technological Advancements and Growing Demand for Early Neurological Diagnosis to Drive Neurology Monitoring Market to USD 17.3 Billion by 2033 at 6.1% CAGR – Coherent Market Insights

Neurology monitoring devices are used to monitor and diagnose neurological conditions. The state of the patient's brain activity is monitored through neurology monitoring devices, such as magnetic resonance imaging (MRI), electroencephalography (EEG) devices, cerebral oximeters, intracranial pressure monitors, and other devices. These devices help monitor both neural and electrical activity in the brain. Different neurology monitoring techniques assess the function of the brain, brainstem, cranial nerves, spinal cord, and peripheral nerves during a procedure. These devices are immensely valuable in the detection and prevention of neurological insult.

Market Statistics

The global Neurology Monitoring Market is estimated to account for US$ 14.1 Bn in terms of value by the end of 2026.

Drivers

Rising Neurological Disease Burden and Demand for Continuous Brain Monitoring

The increasing prevalence of neurological disorders and the growing need for early, accurate, and continuous neurological assessment are major drivers of the neurology monitoring market. The World Health Organization’s Global Status Report on Neurology states that neurological conditions affect more than one-third of the global population and represent the leading cause of ill health and disability worldwide. This substantial patient burden is increasing the use of EEG, EMG, cerebral oxygenation, intracranial pressure, and multimodal brain-monitoring systems.

For instance, in March 2026, Zeto announced three EEG-focused clinical research projects covering continuous stroke monitoring, objective delirium detection, and personalized neuromodulation for drug-resistant epilepsy. The projects use portable, gel-free EEG systems and cloud-based data tools, demonstrating the growing adoption of accessible, real-time neurological monitoring across hospitals and clinical research settings. (Source: WHO; Zeto EG)

Opportunities

Expansion of AI-Enabled Neurological Monitoring

The integration of artificial intelligence with EEG and intracranial brain-monitoring systems presents a significant growth opportunity for the neurology monitoring market. AI-based platforms can analyze large volumes of neurological data, identify abnormal brain activity, reduce interpretation time, and support personalized treatment decisions.

For instance, in May 2026, NeuroPace received U.S. FDA approval for ECoG Assistant, its first AI-driven clinician-enabled feature. The tool uses the company’s long-term intracranial EEG dataset to generate deeper treatment insights and improve the efficiency of epilepsy monitoring and management. (Source: NeuroPace Investors)

Growth of Outpatient and Decentralized EEG Testing

Portable, wireless, dry-electrode, and cloud-connected EEG systems create opportunities to expand neurological monitoring beyond specialized hospital laboratories. In April 2026, Zeto received FDA 510(k) clearance for Zeto New Wave, an outpatient EEG system developed to improve testing access, address EEG staffing constraints, and enhance patient experience in physician practices and clinics. (Source: Zeto EEG)

Adoption of Point-of-Care Brain Imaging in Emerging Markets

Portable neurological imaging systems can address limited access to conventional MRI infrastructure in developing healthcare systems. In April 2026, AIIMS New Delhi initiated routine clinical use of Hyperfine’s portable Swoop MRI system, marking India’s first deployment of bedside brain MRI and creating opportunities for point-of-care neurological assessment in ICUs, emergency departments, trauma units, and underserved regions. (Source: Hyperfine, Inc.)

Restraints

High cost of monitoring devices and dearth of skilled professionals are major factors expected to hamper growth of the global neurology monitoring market over the forecast period. For instance, the average cost of a standard EEG is ~US$ 200 to US$ 700; this procedure can cost as high as US$ 3,000 for extended monitoring. The cost of a magnetic resonance imaging (MRI) also varies based on the place where the test was done, the body part being imaged, and several other factors. Furthermore, since the neurology monitoring equipment is sophisticated, it is likely to be handled by trained personals during operations. This in turn is expected to restrain growth of the market.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/neurology-monitoring-market-5501

Key Takeaways

The global neurology monitoring market was valued at US$ 14.1 Bn in 2026 and is forecast to reach a value of US$ 17.3 Bn by 2033 at a CAGR of 6.1% between 2026 and 2023.

Among product type Magnetic Resonance Imaging (MRI) Devices segment held dominant position in the global neurology monitoring market in 2026, accounting for 37.7% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.

Market Trends

AI-Powered EEG Interpretation is Moving into Routine Clinical Workflows

Artificial intelligence is increasingly being integrated into electroencephalography systems to reduce interpretation time, standardize reporting, and support neurologists facing growing workloads. Newer solutions are moving beyond basic spike or seizure detection toward comprehensive assessment of routine, ambulatory, and long-term EEG recordings. In March 2026, Natus globally launched its autoSCORE AI analysis tool, which assesses multiple clinically relevant EEG abnormalities and provides study-level normal or abnormal classifications. The model was trained on approximately 30,000 expertly labelled EEG recordings and received FDA 510(k) clearance for routine EEG, long-term monitoring, and ambulatory EEG applications. This development is expected to accelerate demand for AI-enabled software subscriptions and integrated neurodiagnostic platforms.

Point-of-Care EEG is Expanding Beyond Seizure Detection

Point-of-care EEG systems are evolving from specialized seizure-detection devices into broader neurological surveillance platforms. Portable hardware combined with AI algorithms allows emergency departments and intensive care units to continuously assess patients who cannot undergo conventional neurological examinations. In January 2026, Ceribell received FDA Breakthrough Device Designation for an investigational large-vessel-occlusion stroke detection monitor that applies an AI algorithm to EEG signals using the company’s existing point-of-care hardware. The designation is not equivalent to FDA marketing clearance for stroke detection, but it illustrates the expanding use of EEG for stroke, delirium, seizure, and other acute neurological conditions. This trend could substantially increase device utilization across non-neurology hospital departments.

Wearable and In-Ear EEG is Enabling Long-Duration Home Monitoring

Neurology monitoring is becoming more decentralized as compact wearable systems allow brain activity to be recorded during sleep, daily activities, and other real-world conditions. These devices may improve the detection of intermittent neurological events that are missed during short hospital-based EEG examinations. At CES 2026, Naox Technologies presented Naox Link, which the company describes as the first FDA-cleared medical-grade in-ear EEG device. The system is intended for neurology, epilepsy, sleep monitoring, and clinical research and supports extended brain monitoring outside conventional laboratories. The emergence of ear-worn EEG platforms is creating opportunities for home-based diagnostics, decentralized clinical trials, longitudinal neurological assessment, and future integration with consumer earables.

No-Mess Electrodes and Cloud Connectivity are Expanding Outpatient EEG Access

Manufacturers are developing EEG systems that require less preparation and fewer specialized technical resources, addressing long patient waiting periods and shortages of trained EEG technologists. In April 2026, Zeto received FDA 510(k) clearance for Zeto New Wave, an outpatient and home EEG system featuring 21 soft-tip, no-mess electrodes arranged according to the standard 10–20 placement system. The platform supports synchronized video and audio, optional ECG, EOG and EMG signals, and recordings of up to 2.5 hours. It also operates through the Zeto Cloud platform, enabling remote access to EEG recordings. Such systems are expected to increase EEG adoption among physician practices, outpatient neurology clinics, community hospitals, and decentralized research facilities.

Quantitative Seizure-Burden Monitoring is Becoming an Outcome-Oriented Biomarker

Neurology monitoring platforms are increasingly converting continuous EEG signals into measurable clinical parameters rather than only generating binary seizure alerts. Seizure-burden measurements can help clinicians prioritize patients, evaluate changes over time, and determine whether treatment is reducing harmful neurological activity. In June 2026, Ceribell announced the publication of a peer-reviewed study involving 359 adult patients across three academic medical centres. Patients with a peak five-minute seizure burden of at least 90% were reported to have 3.4 times higher odds of death or severe disability at discharge compared with patients recording no seizure burden. Each additional hour of AI-assessed seizure activity was associated with an adjusted 1.98-fold increase in risk.

Neonatal and Pediatric Neurological Monitoring is Becoming a Dedicated Growth Area

Device companies are extending point-of-care brain monitoring across wider age groups, particularly neonates and critically ill children who may experience clinically silent seizures. Pediatric-compatible electrodes, age-specific AI algorithms, and rapid bedside EEG systems can reduce dependence on conventional EEG teams and patient transfers. In May 2026, Ceribell reported that it had initiated the commercial launch of its neonatal and pediatric products following successful pilot programs. The company stated that its point-of-care platform combines rapidly deployable EEG hardware with AI-based algorithms for continuous neurological monitoring. Expanding regulatory indications and dedicated pediatric product configurations are likely to support adoption in neonatal intensive care units, pediatric intensive care units, emergency departments, and specialist children’s hospitals.

Monitoring Systems are Progressing from Passive Measurement to Automated Intervention

Neurological monitoring equipment is increasingly being connected with automated treatment or fluid-management functions, particularly in neurocritical care. This transition allows devices to continuously measure neurological parameters while responding according to clinician-defined targets. In January 2026, BrainSpace announced FDA 510(k) clearance for Intellidrop, an automated brain-fluid management system that combines continuous intracranial-pressure measurement with closed-loop, gravity-driven cerebrospinal-fluid drainage. The device can manage drainage according to a personalized pressure or volume target and is indicated for ventricular or lumbar use. This development represents an important movement toward integrated monitoring-and-action platforms that could reduce manual ICU workload and support more consistent management of traumatic brain injury, stroke, hydrocephalus, and neurosurgical patients.

Multimodal Brain Monitoring is Expanding into Ambulatory Surgery Centres

Brain monitoring is increasingly being integrated with broader patient-monitoring platforms that combine EEG-derived anaesthesia-depth measurements, cerebral or regional oxygenation, pulse oximetry, capnography, and other physiological parameters. This integration provides clinicians with a more complete picture of neurological and systemic status during surgery. In January 2026, Medtronic and Mindray expanded their U.S. strategic partnership from hospitals into ambulatory surgery centres. The collaboration includes the integration of Medtronic’s BIS four-channel brain monitoring and INVOS regional oximetry technologies into Mindray monitoring platforms, with additional next-generation systems under integration. The development demonstrates how advanced neurological monitoring is moving beyond tertiary hospitals into outpatient surgical settings where procedure volumes are increasing.

Competitive Landscape

Major players operating in the global neurology monitoring market include Masimo Corporation, Drägerwerk AG & Co. KgaA, Advanced Brain Monitoring Inc., Medtronic plc, Compumedics Limited, Siemens Healthcare GmbH, Koninklijke Philips N.V, Nihon Kohden Corporation, Natus Medical Incorporated, and General Electric Company (GE Healthcare).

Recent Developments

In July 2026, BIOTRONIK Neuro launched Embrace One Proactive Intelligence, an AI-enabled capability supporting patients implanted with the Prospera Spinal Cord Stimulation System. The technology analyzes more than 200 remotely collected data points per patient daily to identify emerging support or therapy-optimization needs. A prospective pilot involving 175 patients reported an 80.9% response rate to proactive outreach, highlighting the growing integration of AI, connected implants, and remote monitoring in neurological care.
In April 2026, Zeto announced U.S. FDA 510(k) clearance for New Wave, a full-montage EEG system developed for outpatient clinics and home settings. The system uses 21 soft-tip, preparation-free electrodes, supports recordings of up to 2.5 hours, and captures synchronized video, audio, ECG, EOG, and EMG signals. Cloud connectivity enables remote access and interpretation, helping clinics expand EEG availability despite shortages of trained technologists. (Source: Zeto EEG)
In January 2026, Ceribell received FDA Breakthrough Device Designation for its large-vessel-occlusion stroke detection and monitoring solution. The innovation uses Ceribell’s point-of-care EEG hardware and an AI algorithm to interpret brain signals for earlier identification of LVO strokes among hospitalized patients. (Source: Ceribell)
In February 2026, NextSense launched Smartbuds, wireless brain-sensing earbuds containing six EEG sensors. The device monitors brain activity in real time and delivers precisely timed audio stimulation based on detected sleep stages, demonstrating the expansion of neurological monitoring into wearable and home-based applications.